About This Webinar
Safely treating lung tumors with ablative doses can be challenging, from central and ultra central to single fraction requires a new level of precision and accuracy. See how Amsterdam University Medical Center is using MRIdian to treat smarter with ablative doses that work harder to destroy tumors and spare healthy tissues. Join this webinar where they will share their experience treating lung cancer with single fraction SABR. With the potential to improve outcomes, reduce side effects and deliver better patient quality of life, is this the future of cancer care? Come see what you may be missing.

About Amsterdam University Medical Center
Amsterdam UMC employs more than 15,000 professionals, treating over 350,000 patients a year at both its sites – AMC and VUmc. Working towards a future in which illnesses are prevented and the best treatment made available to all patients, Amsterdam UMC has developed new methods for diagnostics and treatment together with professionals from other renowned national and international institutions. The institute's main focus is on complex patient care and highly specialized treatment of rare medical conditions. Amsterdam UMC teaches and trains thousands of young people to become doctors, specialists or nurses. Its researchers are clustered in eight research centers so that the institute can achieve its ambition of executing international, cutting-edge research. At Amsterdam UMC, AMC and VUmc are working together on academic patient care, scientific research and teaching and training.
1592322580-006c72d2c04b692a
Miguel Palacios, PhD
Medical Physicist
Miguel Palacios has an MSc degree in Physics and obtained his PhD in 2005 from the Free University of Amsterdam for his research at the Biophysics group. In 2011 he joined the Amsterdam UMC team as a medical physicist to work in the Radiation Oncology department with a focus on treatment planning and the use of MRI for radiotherapy. He has more than four years of clinical experience in the field of MR-guided online adaptive radiotherapy and is co-author of several articles on this subject.
1592322686-b3dc4aebcccf9c20
Prof. Suresh Senan, MD
Professor of Clinical Experimental Radiotherapy
Suresh Senan is the Professor of clinical experimental radiotherapy at the Amsterdam University Medical Centers in the Netherlands. His recent research has focused on the role of immune checkpoint inhibitors in lung malignancies, stereotactic radiotherapy and magnetic resonance-imaging guided adaptive radiotherapy. He is an active member of the European Society for Medical Oncology, the International Association for the Study of Lung Cancer, and ASCO.